06609 HEARTCARE-B
- 17.920
- +0.860+5.04%
HEARTCARE-B News
心瑋醫療-B：年度報告 2023
Interpretation of Xinwei Medical-B (6609.HK) Annual Report: Innovation and Globalization, Therapeutic Products Save Development Potential
The concept of “new quality productivity” was emphasized many times during the two sessions. In particular, the medical device industry, the high-end medical device sector, which is driven by scientific and technological innovation as the core driving force, is undoubtedly also moving towards a rapid development path as an important indicator for measuring the country's level of high-tech development.
Xinwei Medical-B (06609.HK) announced annual results: business focus on driving product structure transformation, gross margin rose to 70.5%, losses narrowed, and major neurointerventional treatment devices are about to be launched
Gelonghui March 28 | Xinwei Medical-B (06609.HK) announced its annual results. For the year ended December 31, 2023, the company's revenue increased to RMB 232.3 million, an increase of 26.9% year on year, and loss before tax narrowed to RMB 102.9 million, a year-on-year decrease of 48.9%. With the expansion of business scale and the effects of cost control and efficiency measures, the company's gross margin increased 2.6 percentage points to 70.5%, and the share of sales and distribution expenses and administrative expenses decreased to 66.2% (2022:91.8%). In 2023, in order to adapt to a rapidly changing city
Xinwei Medical-B (06609) announced 2023 annual results with revenue of 232 million yuan, an increase of 26.9% year-on-year
Xinwei Medical-B (06609) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 232 million yuan (RMB, same below) during the period, an increase of 26.9%; the parent company's owners should have accounted for a loss of 94.012 million yuan, a year-on-year decrease of 53.08%; and a basic loss of 2.47 yuan per share.
HEARTCARE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Xinwei Medical-B (06609.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 18, 丨 Xinwei Medical-B (06609.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and handle any other business.
Home to Linjiang: Brain-computer interface is a trend where Hong Kong stocks are not approved
As an emerging industry, brain-computer interface technology is mainly divided into hardware layer and software layer.
Hong Kong Stock Concept Tracking | Brain-computer interface ushered in a “milestone moment” Musk announced: the first time humans have implanted a brain-computer interface chip (with concept stock)
Musk announced on social networking platform X that the first human being received an implant from the brain-computer interface company Neuralink is recovering well.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Shanghai HeartCare Offloads Stake in Medical Device Developer Shenji Medical
Shanghai HeartCare Medical Technology (HKG:6609) sold its entire stake in subsidiary Shanghai Shenji Medical Technology to a group of purchasers for 9 million yuan, a Monday filing said. The buyers of
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Xinwei Medical-B plans to sell all of Shenji Medical's shares for 9 million yuan
Xinwei Medical-B (06609) announced that on December 11, 2023 (after the trading period), the company signed a share transfer agreement with buyers Xing Tingyu, Li Meng, Shenji employee shareholding platform and Value Magnet Limited. Based on this, the company conditionally agreed to sell all of its shares in Shenji Medical to the buyer at a total cost of RMB 9 million. Shenji Medical is a limited company incorporated in China and a wholly-owned subsidiary of the company. The company mainly focuses on medical device development that relies on computer-aided technology. Shenji Medical was founded by the company, Li Meng and Xing Ting
Xinwei Medical-B (06609.HK) plans to sell all of Shenji Medical's shares for 9 million yuan
Gelonghui December 11丨Xinwei Medical-B (06609.HK) announced that on December 11, 2023, the company signed an equity transfer agreement with the buyer. Based on this, the company conditionally agreed to sell all of its shares in Shenji Medical to the buyer at a total cost of RMB 9 million. After the handover, the company will no longer have any interest in Shenji Medical, and the company will no longer be a subsidiary of the company. Shenji Medical is a limited company incorporated in China and a wholly-owned subsidiary of the company. The company mainly focuses on medical device development that relies on computer-aided technology. Shenji Medical was founded by the company, by Li
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Xinwei Medical-B (06609): Xue Zongyu was elected Chairman of the Supervisory Board
According to the Zhitong Finance App, Xinwei Medical-B (06609) issued an announcement. At the company's board of supervisors meeting held on November 17, 2023, Mr. Xue Zongyu was elected as the chairman of the board of supervisors. His term of office runs from November 17, 2023 to the end of the term of the second board of supervisors, effective immediately.
Hong Kong stock concept tracking | Is the next generation of human-computer interaction methods coming for Musk's brain-computer interface project to recruit “mice”? (with concept stock)
Recently, according to a CCTV financial report, Musk's “Neural Connect” company's brain-computer interface project is recruiting volunteers and will conduct human clinical trials.
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
HEARTCARE-B: INTERIM REPORT 2023
HeartCare Medical Technology's Loss Narrows in H1
Shanghai HeartCare Medical Technology (HKG:6609) recorded a loss attributable to owners of 54.3 million yuan in the first half, narrowing from the year-ago loss of 66.8 million yuan. Loss per share wa
Analysis
Price Target
No Data
